Clinical Trial

A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors

Enrolling by Invitation Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated May 28, 2025 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the safety and tolerability of HB0052 in patients with advanced solid tumors
Trial Details
NCT Number NCT06992687
Lead Sponsor Shanghai Huaota Biopharmaceutical Co., Ltd.
Collaborators: Peking University Cancer Hospital & Institute, Zhejiang Cancer Hospital, Shandong Cancer Hospital and Institute, Hunan Cancer Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The Second Affiliated Hospital of Harbin Medical University, Huazhong University of Science and Technology
Conditions Solid Tumors
Enrollment 30 participants
Start Date 2024-09-01
Primary Completion 2025-09-30 (estimated)
Study Completion 2025-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-28